drugset / Trial / NCT05955326

Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05955326 ↗

Phase 4 Recruiting 160 enrolled Pharmazz, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a prospective, multicenter, randomized, double-blind, parallel, phase IV study designed to evaluate the safety and efficacy of sovateltide (PMZ-1620, IRL-1620) as a potential treatment for cerebral ischemic stroke.

Timeline

Start
2024-01-08
Primary completion
2026-02
Completion
2026-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject SOVATELITIDE Peptide 0.3 ug/kg Intravenous

Indications